Adam S Sperling
Overview
Explore the profile of Adam S Sperling including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
69
Citations
2416
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Frenking J, Zhou X, Wagner V, Hielscher T, Kauer J, Mai E, et al.
J Immunother Cancer
. 2024 Oct;
12(10).
PMID: 39379098
Background: Chimeric antigen receptor (CAR) T-cell therapy has demonstrated significant benefits in the treatment of relapsed/refractory multiple myeloma (RRMM). However, these outcomes can be compromised by severe complications, including cytokine...
3.
Parekh M, Adhikari Y, Deshpande N, Miller P, Sperling A, Tesfaigzi Y, et al.
Exp Eye Res
. 2024 Sep;
248:110089.
PMID: 39265717
Epidemiological studies show cigarette smoking enhances corneal endothelial dysfunction, but mechanisms remain unclear. Our study reveals that prolonged smoke exposure activates the aryl hydrocarbon receptor (AhR), increasing CYP1B1 expression and...
4.
Liu Y, Mo C, Hartley-Brown M, Sperling A, Midha S, Yee A, et al.
Expert Rev Hematol
. 2024 Jul;
17(8):445-465.
PMID: 39054911
Introduction: The treatment of multiple myeloma (MM) is evolving rapidly. Quadruplet regimens incorporating proteasome inhibitors, immunomodulatory drugs (IMiDs), and CD38 monoclonal antibodies have emerged as standard-of-care options for newly diagnosed...
5.
Jiang W, Shaw S, Rush J, Dumont N, Kim J, Singh R, et al.
bioRxiv
. 2024 Jun;
PMID: 38826457
Protein phosphatase, Mg/Mn dependent 1D (PPM1D), is a serine/threonine phosphatase that is recurrently activated in cancer, regulates the DNA damage response (DDR), and suppresses the activation of p53. Consistent with...
6.
Ghobrial I, Gormley N, Kumar S, Mateos M, Bergsagel P, Chesi M, et al.
Blood Cancer Discov
. 2024 Mar;
5(3):146-152.
PMID: 38441243
While the current approach to precursor hematologic conditions is to "watch and wait," this may change with the development of therapies that are safe and extend survival or delay the...
7.
Chen C, Zhang L, Dutta R, Niroula A, Miller P, Gibson C, et al.
Cell Stem Cell
. 2024 Feb;
31(2):275-277.
PMID: 38306995
No abstract available.
8.
Stevens M, Kimmerling R, Olcum S, Vacha M, LaBella R, Minnah A, et al.
JCO Precis Oncol
. 2024 Jan;
8:e2300349.
PMID: 38237098
Purpose: Cancer patients with advanced-stage disease have poor prognosis, typically having limited options for efficacious treatment, and genomics-based therapy guidance continues to benefit only a fraction of patients. Next-generation ex...
9.
Saygin C, Zhang P, Stauber J, Aldoss I, Sperling A, Weeks L, et al.
Blood Cancer Discov
. 2023 Dec;
5(3):164-179.
PMID: 38150184
Significance: CH is a precursor lesion for lymphoblastic leukemogenesis. ALL with MyM has distinct genetic and clinical characteristics, associated with adverse survival outcomes after chemotherapy. CH can precede ALL years...
10.
Bourgeois W, Cutler J, Aubrey B, Wenge D, Perner F, Martucci C, et al.
Blood
. 2023 Dec;
143(15):1513-1527.
PMID: 38096371
Small molecules that target the menin-KMT2A protein-protein interaction (menin inhibitors) have recently entered clinical trials in lysine methyltransferase 2A (KMT2A or MLL1)-rearranged (KMT2A-r) and nucleophosmin-mutant (NPM1c) acute myeloid leukemia (AML)...